Search Results - "KEHUA WU"

Analysis on the geographical pattern and driving force of traditional villages based on GIS and Geodetector: a case study of Guizhou, China by Wu, Kehua, Su, Weici, Ye, Shi’an, Li, Wei, Cao, Yang, Jia, Zhenzhen

“…Traditional villages have received widespread attention from all walks of life based on important carriers of Chinese rural culture. The mutual superposition…”
Get full text

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer by INNOCENTI, Federico, SCHILSKY, Richard L, KARRISON, Theodore, MAITLAND, Michael L, SALGIA, Ravi, RATAIN, Mark J, RAMIREZ, Jacqueline, JANISCH, Linda, UNDEVIA, Samir, HOUSE, Larry K, DAS, Soma, KEHUA WU, TURCICH, Michelle, MARSH, Robert

“…The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active…”
Get full text

Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver by Liu, Wanqing, Ramírez, Jacqueline, Gamazon, Eric R, Mirkov, Snezana, Chen, Peixian, Wu, Kehua, Sun, Chang, Cox, Nancy J, Cook, Jr, Edwin, Das, Soma, Ratain, Mark J

“…The aim of this study was to discover cis- and trans-acting factors significantly affecting mRNA expression and catalytic activity of human hepatic…”
Get full text

Personalized targeted therapy for lung cancer by Wu, Kehua, House, Larry, Liu, Wanqing, Cho, William C S

“…Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical…”
Get full text

Curriculum-reinforcement learning on simulation platform of tendon-driven high-degree of freedom underactuated manipulator by Or, Keung, Wu, Kehua, Nakano, Kazashi, Ikeda, Masahiro, Ando, Mitsuhito, Kuniyoshi, Yasuo, Niiyama, Ryuma

“…A high degree of freedom (DOF) benefits manipulators by presenting various postures when reaching a target. Using a tendon-driven system with an underactuated…”
Get full text

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients by COHEN, Ezra E. W, KEHUA WU, HOUSE, Larry, RAMIREZ, Jacqueline, UNDEVIA, Samir D, FLEMING, Gini F, GAJEWSKI, Thomas F, RATAIN, Mark J, HARTFORD, Christine, KOCHERGINSKY, Masha, NAPOLI EATON, Kimberly, YUANYUAN ZHA, NALLARI, Anitha, MAITLAND, Michael L, FOX-KAY, Kammi, MOSHIER, Kristin

“…Sirolimus is the eponymous inhibitor of the mTOR; however, only its analogs have been approved as cancer therapies. Nevertheless, sirolimus is readily…”
Get full text

Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients by SHARMA, Manish R, KARRISON, Theodore G, SCHILSKY, Richard L, RATAIN, Mark J, COHEN, Ezra E. W, KELL, Bethany, KEHUA WU, TURCICH, Michelle, GEARY, David, KANG, Soonmo P, TAKEBE, Naoko, GRAHAM, Richard A, MAITLAND, Michael L

“…Vismodegib, an orally bioavailable small-molecule Smoothened inhibitor, is approved for treatment of advanced basal cell carcinoma (BCC). We conducted a…”
Get full text

Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs by KEHUA WU, HOUSE, Larry, RAMIREZ, Jacqueline, SEMINERIO, Michael J, RATAIN, Mark J

“…There are many phase I trials of oncology drug combinations, very few of which report clinically significant pharmacokinetic interactions. We hypothesized that…”
Get full text

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies by GANGADHAR, Tara C, COHEN, Ezra E. W, FLEMING, Gini F, RATAIN, Mark J, KEHUA WU, JANISCH, Linda, GEARY, David, KOCHERGINSKY, Masha, HOUSE, Larry K, RAMIREZ, Jackie, UNDEVIA, Samir D, MAITLAND, Michael L

“…Sirolimus is the prototypical mTOR inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR)…”
Get full text

Population Pharmacokinetics of Modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui Healthy Subjects Determined by Nonlinear Mixed-Effects Modeling by Tao, Guo, Longshan, Zhao, Kehua, Wu, Dongya, Xia, Wei, Lu, Zheng, Guan, Chenhui, Deng

“…Modafinil is being used as a novel wake-promoting psychostimulant. To develop rational dosing schemes, given that China has 56 ethnicities that may have…”
Get full text

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients by Ramírez, Jacqueline, Wu, Kehua, Janisch, Linda, Karrison, Theodore, House, Larry K., Innocenti, Federico, Cohen, Ezra E. W., Ratain, Mark J.

“…Purpose Irinotecan and thalidomide are commonly administered antineoplastic drugs. Combination treatment may potentiate their antitumor effect and protect…”
Get full text

Surface modification of segmented poly(ether urethane) by grafting sulfo ammonium zwitterionic monomer to improve hemocompatibilities by Jun, Zhang, Youling, Yuan, Kehua, Wu, Jian, Shen, Sicong, Lin

“…Segmented poly(ether urethane) (SPEU) was synthesized from 4,4′-diphenylmethane-diisocyanate, polytetramethylene glycol and 1,4-butandiol. SPEU was…”
Get full text

Conservation of stone heritage buildings: Exploring the algicidal properties of biologically-synthesized nano-silver by Long, Mingzhong, Xu, Zhiyi, Chen, Yingqiu, Wu, Kehua, Yang, Shengyu

“…The degradation of stone heritage buildings by pioneer plants such as algae is a major challenge in heritage conservation research worldwide. At present, there…”
Get full text

Personalized targeted therapy for lung cancer by Wu, Kehua, House, Larry, Liu, Wanqing, Cho, William C S

“…由于每一肺癌患者在临床特征、预后、治疗反应和耐受性方面的进展都是独特的，所以肺癌被认为是异质性疾病。个体化用药是指运用标志物来预测哪些患者更易获益于某种治疗。对于肺癌而言，日趋完善的表皮生长因子受体（epidermal growth factor receptor,…”
Get full text

Next-generation sequencing for lung cancer by Wu, Kehua, Huang, R Stephanie, House, Larry, Cho, William Chi

“…肺癌在生物学上具有侵袭性，并且是癌症相关死亡的主要原因。根据临床特征、预后、对治疗的反应和耐受性，每一例肺癌患者的进展均是独特的。传统上基于毛细管的单基因测序的第一代技术（如Sanger测序法）已被允许大量平行测序且成本更低、通量更高的下一代测序技术（next-generation sequencing,…”
Get full text

Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells by Wang, Siyuan, Mou, Zhenzhen, Ma, Yuanheng, Li, Jian, Li, Jingyun, Ji, Xiwei, Wu, Kehua, Li, Liang, Lu, Wei, Zhou, Tianyan

“…Growing evidence suggests that the efficacy of sunitinib in breast cancer may be limited by increasing the population of cancer stem-like cells (CSCs). Hence…”
Get full text

Significance of the preservation of 'pseudo-thumb' in fossil skeletons of giant panda (ailuropoda melanoleuca) in Shuanghe Cave, Guizhou Province, southern China by Wang, Deyuan, Gao, Zhandong, Bottazzi, Jean, Shao, Qingfeng, Li, Youwei, Wu, Kehua, Zhou, Wenlong, Jiao, Fu, Li, Shijie, Jiangzuo, Qigao

“…The age when the giant panda (Ailuropoda melanoleuca) transitioned to a bamboo dominant diet has not been well established due to the lack of fossil evidence…”
Get full text

Next-generation sequencing for lung cancer by Wu, Kehua, Huang, R Stephanie, House, Larry, Cho, William Chi

“…Lung cancer is biologically aggressive and is the leading cause of cancer-related deaths. The development of lung cancer is unique in each patient according to…”
Get more information

Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) by Sharma, Manish R., Mehrotra, Shailly, Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford, Winer, Eric P., Lyss, Alan P., Toppmeyer, Deborah L., Moreno‐Aspitia, Alvaro, Lad, Thomas E., Velasco, Mario, Overmoyer, Beth, Rugo, Hope S., Ratain, Mark J., Gobburu, Jogarao V.

“…Chemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed…”
Get full text

Evaluation of utility of pharmacokinetic studies in phase I combination trials by Wu, Kehua, House, Larry, Ramirez, Jacqueline, Ratain, Mark J.

“…Abstract only 2611 Background: There are many phase I clinical combination trials including drug-drug interaction (DDI) studies, but very few of them report…”
Get full text